Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacogenomics of neurodegenerative diseases
Autore:
Maimone, D; Dominici, R; Grimaldi, LME;
Indirizzi:
Osped Garibaldi, Dept Neurol, I-95123 Catania, Italy Osped Garibaldi Catania Italy I-95123 ept Neurol, I-95123 Catania, Italy San Raffaele Sci Inst, Dipartimento Neurosci, I-20132 Milan, Italy San Raffaele Sci Inst Milan Italy I-20132 Neurosci, I-20132 Milan, Italy AUSL 2 Reg Siciliana, Dipartimento Neurosci, Ctr Mem & Demenze, I-93100 Caltanissetta, Italy AUSL 2 Reg Siciliana Caltanissetta Italy I-93100 00 Caltanissetta, Italy
Titolo Testata:
EUROPEAN JOURNAL OF PHARMACOLOGY
fascicolo: 1, volume: 413, anno: 2001,
pagine: 11 - 29
SICI:
0014-2999(20010209)413:1<11:POND>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMYOTROPHIC-LATERAL-SCLEROSIS; ONSET ALZHEIMERS-DISEASE; SPORADIC PARKINSONS-DISEASE; GLUTAMATE TRANSPORTER SUBTYPES; HEAVY NEUROFILAMENT SUBUNIT; LIPOPROTEIN VLDL RECEPTOR; NEUROTROPHIC FACTOR GENE; TRANSGENIC MOUSE MODEL; MOTOR-NEURON DISEASE; AMYLOID-BETA PEPTIDE;
Keywords:
amyotrophic lateral sclerosis; Parkinson disease; Alzheimer disease; gene polymorphism; gene mutation; pharmacogenomics;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
187
Recensione:
Indirizzi per estratti:
Indirizzo: Grimaldi, LME Univ Milan, San Raffaele Sci Inst, Dept Neurol, NeuroimmunolUnit,DIBIT, Via Olgettina 58, I-20132 Milan, Italy Univ Milan Via Olgettina 58 Milan Italy I-20132 ilan, Italy
Citazione:
D. Maimone et al., "Pharmacogenomics of neurodegenerative diseases", EUR J PHARM, 413(1), 2001, pp. 11-29

Abstract

Current knowledge of sporadic degenerative disorders suggests that, despite their multifactorial etiopathogenesis, genetics plays a primary role in orchestrating the pathological events, and even dramatically changes the disease phenotype from patient to patient. Genes may act as susceptibility factors, increasing the risk of disease development, or may operate as regulatory factors, modulating the magnitude and severity of pathogenic processes or the response to drug treatment. The goal of pharmacogenomics is the application of this knowledge to elaborate more specific and effective treatments and to tailor therapies to individual patients according to their genetic profile. Here, we outline the leading theories on the etiopathogenesis ofneurodegenerative diseases. including amyotrophic lateral sclerosis. Parkinson's disease, and Alzheimer disease. and we review the potential role of genetic variations, such as gene mutations and polymorphisms, in each context. We also suggest potential targets for new therapeutic approaches and variability factors for current treatments based on genotype features. Finally, we propose a few options of preventive therapeutic interventions in patients with a high genetic risk of disease. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 14:34:35